Coronado Biosciences starts Phase 2 ulcerative colitis study with TSO

Coronado Biosciences (CNDO) initiates a Phase 2 study of CNDO-201 in patients with ulcerative colitis.

The trial is sponsored by the National Institutes of Health and will "evaluate the [drug's] effect on clinical response of UC, intestinal mucosal immunological response, and inflammatory markers."

Primary endpoint is clinical response.

This is the third Phase 2 trial for CNDO-201. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs